BCIQ Profiles

Company Profile Report

Santhera sags on FDA delay for Raxone

Santhera Pharmaceuticals Holding AG (SIX:SANN) sank CHF30.85 (37%) to CHF52.65 on Thursday after it said FDA would not support its plan to submit an

Read the full 240 word article

How to gain access

Continue reading with a
two-week free trial.